ArticleArXiv2026
GOLDMARK: Governed Outcome-Linked Diagnostic Model Assessment Reference Kit.
Article in ArXiv, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Background: Computational biomarkers (CBs) are histopathology-derived patterns extracted from hematoxylin-eosin (H&E) whole-slide images (WSIs) using artificial intelligence (AI) to predict therapeutic response or prognosis. Recently, slide-level Methods: We introduce Results: We evaluated 33 tumor-biomarker tasks; aggregate summaries over the 33 tasks with complete reciprocal metric coverage yielded mean AUROC of 0.689 (TCGA) and 0.630 (MSKCC). Restricting analysis to the eight highest-performing tasks yielded mean AUROCs of 0.831 and 0.801, respectively. These tasks correspond to established morphologic-genomic associations (e.g., LGG Conclusions: Computational pathology is entering a translational phase in which reproducibility, transparency, and cross-institutional robustness are prerequisites for clinical trust. GOLDMARK establishes a reference framework that separates dataset curation from model evaluation and introduces structured intermediate artifacts, quality-control metadata, and symmetric cross-dataset testing as core components of benchmarking. Such infrastructure is essential for transforming computational biomarkers from research demonstrations into reproducible, clinically trusted workflows.
Identifiers
41907586PMC13019446What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.